Brett Shandler advises life science clients on licensing, intellectual property, regulatory, and corporate matters.

Prior to joining Latham, Mr. Shandler acted in patent litigation and regulatory matters involving pharmaceuticals, biologics, genetic technologies, and medical devices. He also gained experience defending high-value damages claims brought by government health departments.

Mr. Shandler also has experience in technology matters, and has a particular interest in IP and antitrust issues arising in the context of standard essential patents (SEP) and fair, reasonable, and non-discriminatory (FRAND) licensing.

Mr. Shandler has been recognized as a Rising Star by Managing IP.

Mr. Shandler’s experience includes advising and/or acting for:

Life Sciences

  • Various leading life science companies on pharmaceutical regulatory matters, including in relation to registration, reimbursement, compliance, and clinical trial protocols.*
  • Various life science companies on IP and regulatory issues relating to COVID-19.*
  • Leading biosimilar manufacturer regarding European market entry strategy for well‑known blockbuster biologic.*
  • Leading biopharmaceutical company on the protection of blockbuster biologic product.*
  • Leading biotechnology company in patent litigation proceedings concerning the use of transgenic mice as a therapeutic antibody development platform.*
  • Neuroscience drug discovery and development company in patent litigation proceedings concerning extended‑release melatonin product for the treatment of insomnia.*
  • Leading biopharmaceutical company in patent proceedings against biosimilar manufacturer in relation to process patents used to manufacture fusion protein product.*
  • Leading medical device company in patent litigation proceedings relating to medical devices for the treatment of sleep apnea.*
  • Global medical device company in patent litigation proceedings concerning transcatheter heart valve technology.*
  • Leading biopharmaceutical company in defense against high-value damages claims brought by generic and government claimants pursuant to cross-undertakings in damages following ultimate finding of patent invalidity.*


  • Multinational electronics company in relation to the expiry of SEP cross‑license.*
  • Leading electronics company in its UK defense of a SEP infringement claim and claim for FRAND relief, and in the coordination of parallel French proceedings.*
  • Leading technology company on FRAND/SEP policy issues.*

Pro Bono

  • US professional tennis player in successful appeal against Grand Slam Board fine for not playing to professional standard in French Open.*

*Matter handled prior to joining Latham

Bar Qualification

  • New South Wales (Australia)


  • Postgraduate Diploma in Intellectual Property Law and Practice, University of Oxford, 2020
  • Master of Laws (LL.M.), University of Melbourne, Melbourne Law School, 2019
  • Certificate in Transnational Legal Studies, Center for Transnational Legal Studies, Georgetown University, 2016
  • Juris Doctor, University of Melbourne, Melbourne Law School, 2016
  • Bachelor of Biomedical Science, Monash University, 2012

Languages Spoken

  • English